Anti-Vibrio cholerae O1 & O139 Monoclonal Antibodies for Cholera Rapid Diagnostic Test Development
Vibrio cholerae is a gram-negative, comma-shaped, motile bacterium belonging to the family Vibrionaceae. It is the causative agent of cholera, one of the world's most rapidly progressing infectious diseases — capable of causing severe watery diarrhea, dehydration, and death within hours of symptom onset if untreated. The bacterium produces the potent cholera toxin (CT), which acts on intestinal epithelial cells to cause massive fluid secretion — producing the characteristic "rice water" diarrhea that can reach 20 liters per day in severe cases. Without rapid oral or intravenous rehydration therapy, cholera case fatality rates can exceed 25–50%; with adequate treatment, fatality drops to below 1%. The World Health Organization estimates 1.3–4 million cholera cases and 21,000–143,000 deaths occur annually, predominantly in sub-Saharan Africa and South Asia.
Among more than 200 O serogroups of V. cholerae identified based on somatic (O) antigen variability, only two cause epidemic and pandemic cholera: serogroup O1 and serogroup O139. The O1 serogroup is responsible for all seven documented global cholera pandemics, including the current 7th pandemic that began in 1961 and continues today. O1 is further divided into two biotypes — Classical (responsible for pandemics 1–6) and El Tor (responsible for the 7th pandemic, now dominant worldwide) — and three serotypes — Ogawa (antigens A and B), Inaba (antigens A and C), and the rare Hikojima (antigens A, B, and C). The O139 Bengal serogroup emerged in 1992 in Bangladesh and India, causing the first epidemic since 1961 not caused by O1. O139 is phylogenetically related to El Tor O1 but has acquired a distinct capsular polysaccharide (CPS) locus that replaces the O1 LPS, rendering it antigenically distinct and not cross-protected by O1 immunity.
For IVD assay development, cholera rapid diagnostic tests (RDTs) use a lateral flow sandwich immunoassay format to detect V. cholerae O1 and O139 antigens directly in stool or rectal swab specimens. Rapid diagnosis is critical in cholera outbreak settings — particularly in refugee camps, post-disaster zones, and low-resource healthcare settings in endemic regions — where laboratory culture infrastructure is unavailable and treatment delays are life-threatening. WHO prequalified cholera RDTs use matched monoclonal antibody pairs targeting the O1 and O139 LPS antigens. Sekbio's cholera antibody panel provides IVD developers with characterized O1 (S20-O1-3019, S20-O1-3020) and O139 (S20-O139-3021, S20-O139-3022) monoclonal antibodies, plus S14-Cholera-w001, all produced by hybridoma technology in mice using purified VC antigen immunogens, validated for immunologic diagnosis applications.
Five monoclonal antibodies covering V. cholerae O1 and O139 serogroups for complete cholera rapid diagnostic test development.
| Catalog No. | Target | Host / Source | Concentration | Purity | Titer | Storage |
|---|---|---|---|---|---|---|
| S20-O1-3019 | Anti-V. cholerae O1 mAb | Mouse / Ascites | 5.0 mg/ml | >90% SDS-PAGE | >1:100,000 ELISA | −20°C / +4°C |
| S20-O1-3020 | Anti-V. cholerae O1 mAb | Mouse / Ascites | 5.0 mg/ml | >90% SDS-PAGE | >1:100,000 ELISA | −20°C / +4°C |
| S20-O139-3021 | Anti-V. cholerae O139 mAb | Mouse / Ascites | 5.0 mg/ml | >90% SDS-PAGE | >1:100,000 ELISA | −20°C / +4°C |
| S20-O139-3022 | Anti-V. cholerae O139 mAb | Mouse / Ascites | 5.0 mg/ml | >90% SDS-PAGE | >1:100,000 ELISA | −20°C / +4°C |
| S14-Cholera-w001 | Anti-V. cholerae mAb | Mouse | Contact us | >90% SDS-PAGE | Contact us | −20°C |
All antibodies supplied in PBS pH 7.2 liquid format. MOQ 1 mg. Full COA provided with each lot. Contact info@sekbio.com for matched pair evaluation kits and bulk OEM pricing.
Characterized O1 and O139 antibody pairs engineered for the sensitivity and specificity required in field-deployable cholera rapid diagnostic tests.
WHO guidelines recommend cholera RDTs that detect both O1 and O139 serogroups, since either can cause epidemic disease. Sekbio provides separate matched antibody pairs for O1 (S20-O1-3019/3020) and O139 (S20-O139-3021/3022), enabling a single dual-line LFA strip that simultaneously reports O1 and O139 status. This complete serogroup coverage is essential for test performance during outbreaks — where serogroup identification guides public health response and vaccination strategies. No single O1 antibody will detect O139 strains, making dual coverage a non-negotiable design requirement for outbreak-ready RDTs.
All Sekbio cholera monoclonal antibodies achieve ELISA titer >1:100,000 against purified VC O1 or O139 antigen. High antibody titer reflects strong antigen-binding affinity, which translates directly to LFA test sensitivity — enabling antigen detection in the early stages of cholera infection when stool bacterial loads may not yet be at peak levels. In LFA format, high-affinity antibodies allow thinner colloidal gold conjugate bands, reduced background, and sharper positive line signals. This is particularly important in field settings where sample concentrations may be variable due to patient hydration status.
All Sekbio cholera monoclonal antibodies are produced from mouse ascites, a production method that delivers high antibody concentrations (5.0 mg/ml) suitable for direct conjugation and membrane coating in LFA manufacturing without extensive concentration steps. Ascites-derived antibodies provide high purity (>90% by SDS-PAGE) and consistent lot-to-lot performance when produced under controlled conditions. The 5.0 mg/ml concentration allows direct dilution to working concentrations for colloidal gold conjugation (typically 10–50 μg/ml) or nitrocellulose membrane striping (0.5–2 mg/ml) without additional protein concentration.
Cholera RDTs must function reliably in field conditions — high ambient temperatures, limited cold chain infrastructure, and use by non-laboratory health workers. Sekbio's cholera antibodies are validated for LFA format (the platform of choice for outbreak field testing) and can withstand conditions typical of sub-Saharan African and South Asian deployment. The antibodies' stability at −20°C (≥3 years) and +4°C (1–2 weeks) ensures cold chain compatibility with standard LFA kit storage requirements. IVD manufacturers targeting WHO prequalification for cholera RDTs can use Sekbio's antibodies as the immunoreagent backbone.
Sekbio's cholera antibodies are validated for immunologic diagnosis applications covering both lateral flow assay (LFA) sandwich format — the primary platform for cholera point-of-care diagnosis — and ELISA for quantitative antigen detection, epidemiological surveillance, and laboratory confirmation testing. Multi-platform validation allows IVD developers to use a single antibody source for both rapid test strip kits (for field use) and ELISA plate kits (for laboratory confirmation and reference testing), simplifying supply chain management and reducing raw material qualification costs.
MOQ 1 mg for R&D evaluation; OEM quantities from 10 mg to gram scale available for LFA kit manufacturing. Sekbio's ISO 13485-certified manufacturing in Shenzhen provides quality-assured cholera antibody production with batch release COA documentation. Sub-Saharan Africa and South Asia account for the majority of global cholera burden — and represent the primary commercial markets for cholera RDT manufacturers. Sekbio supports IVD partners developing CE-marked or WHO-prequalified cholera diagnostic tests for humanitarian and government procurement channels. Contact info@sekbio.com for OEM supply agreements and matched pair evaluation kits.
Validated for cholera outbreak rapid diagnosis, epidemiological surveillance, point-of-care testing, and OEM LFA kit manufacturing.
In cholera outbreak settings — refugee camps, post-flood zones, urban informal settlements — rapid confirmatory diagnosis is essential for triggering the cholera outbreak response protocol (oral rehydration therapy deployment, water chlorination, contact tracing, vaccination campaigns). WHO's 2016 Global Task Force on Cholera Control (GTFCC) recommends cholera RDTs for field-based outbreak detection, particularly in areas without laboratory infrastructure. Sekbio's O1 and O139 antibodies enable the development of RDTs that deliver results within 15 minutes from fresh stool or rectal swab specimens, without laboratory equipment or trained personnel. Countries with high cholera burden — Democratic Republic of Congo, Yemen, Nigeria, Ethiopia, Haiti — represent the key deployment markets for outbreak diagnostic kits.
V. cholerae environmental surveillance in water bodies, drinking water supplies, and sewage systems is an important tool for cholera risk assessment and early warning before human cases appear. LFA-based cholera antigen detection tests developed from Sekbio's antibodies can be adapted for concentrated water sample testing — enrichment in alkaline peptone water (APW) followed by antigen detection — enabling surveillance of environmental V. cholerae O1 and O139 in rivers, reservoirs, and water distribution networks. This is particularly relevant in countries like Bangladesh, India, and DRC where cholera is endemic and environmental persistence of V. cholerae is an ongoing public health challenge. Visit our Products page to explore our full infectious disease antibody portfolio.
ELISA-based cholera antigen quantification using Sekbio's O1 and O139 antibodies supports epidemiological surveillance laboratories monitoring cholera incidence in endemic regions. ELISA format provides quantitative antigen data useful for tracking outbreak progression, comparing attack rates between communities, and evaluating the efficacy of control interventions (water treatment, vaccination coverage). National and regional public health reference laboratories in Africa and Asia that conduct cholera surveillance programs can use Sekbio's antibody pairs for developing and validating ELISA-based quantitative cholera antigen assays as complementary tools to culture-based confirmation methods.
IVD companies developing cholera rapid test kits for sale in Africa, South Asia, Southeast Asia, and Latin America can source matched O1 and O139 antibody pairs from Sekbio for integration into their LFA manufacturing processes. Sekbio provides both capture and detection antibody candidates (two O1 clones: S20-O1-3019 and S20-O1-3020; two O139 clones: S20-O139-3021 and S20-O139-3022), allowing manufacturers to select optimal capture/detector combinations based on their specific LFA membrane and conjugate pad configurations. We support CE marking, WHO prequalification, and NMPA regulatory documentation. Contact our team for matched pair evaluation kits, conjugation protocols, and bulk supply pricing.
Technical and commercial questions from IVD R&D engineers and procurement teams developing cholera rapid diagnostic tests.
Cholera is caused by Vibrio cholerae, a gram-negative bacterium producing cholera toxin that causes severe watery diarrhea. Among 200+ O serogroups, only O1 and O139 cause epidemic cholera. O1 (responsible for the 7th pandemic) includes biotypes Classical and El Tor, and serotypes Ogawa and Inaba. O139 (Bengal serogroup) emerged in 1992 and is antigenically distinct from O1. WHO recommends that cholera RDTs detect both O1 and O139 — antibodies targeting O1 do not cross-react with O139 and vice versa. Sekbio provides separate antibody pairs for both serogroups.
S20-O1-3019 and S20-O1-3020 detect V. cholerae O1 antigen (raised against purified VC O1 immunogen). S20-O139-3021 and S20-O139-3022 detect V. cholerae O139 antigen (raised against purified VC O139 immunogen). These two pairs have no cross-reactivity with each other's targets — they must be used together to provide complete diagnostic coverage. S14-Cholera-w001 is an additional cholera antibody; contact info@sekbio.com for technical specifications.
Yes. All Sekbio cholera antibodies are validated for immunologic diagnosis applications, specifically LFA (lateral flow assay) sandwich format. In a standard cholera LFA, one antibody is colloidal gold-conjugated as the detector antibody, and a second antibody is membrane-immobilized as the capture antibody. Sekbio provides two clones per serogroup (3019/3020 for O1; 3021/3022 for O139), enabling matched pair optimization for capture and detection roles. Contact info@sekbio.com for conjugation and membrane striping protocols.
Long-term: −20°C (shelf life ≥3 years). Short-term: +4°C (1–2 weeks). After first thaw, centrifuge and aliquot to avoid repeated freeze-thaw cycles. Supplied in 0.01M PBS, pH 7.2, at 5.0 mg/ml. Full Certificate of Analysis (COA) provided with each shipment. Purity ≥90% by SDS-PAGE. ELISA titer >1:100,000.
MOQ is 1 mg for R&D and assay development. OEM quantities from 10 mg to gram scale are available for LFA kit manufacturing. Sekbio's ISO 13485-certified facility in Shenzhen supports high-volume supply for cholera RDT manufacturers serving African and Asian markets. Contact info@sekbio.com for matched pair evaluation kits, OEM supply agreements, and bulk pricing. We support CE marking, WHO prequalification, and NMPA regulatory documentation.
Cholera LFA tests built on Sekbio's antibodies are compatible with fresh liquid stool (the "rice water" stool characteristic of severe cholera — the preferred sample type for highest sensitivity), rectal swab eluate, stool enrichment broth (alkaline peptone water after 6–8 hours incubation to amplify V. cholerae), and environmental water samples after APW enrichment. WHO-recommended sample types for field cholera RDT use are fresh liquid stool or rectal swab. Contact info@sekbio.com for sample type compatibility data and LFA development technical support.
Sekbio's O1 antibodies (S20-O1-3019/3020) are raised against purified VC O1 antigen and are designed for O1 serogroup-specific detection. Non-O1/non-O139 V. cholerae strains lack the O1 LPS antigen and are not detected by O1-specific antibodies — which is consistent with the clinical reality that non-O1/non-O139 strains do not cause epidemic cholera. This serogroup specificity is a feature, not a limitation, for diagnostic purposes. Contact info@sekbio.com for cross-reactivity data across other Vibrio species and enteric pathogens.
Request matched pair evaluation kits for O1 and O139 antibodies, or discuss OEM supply for cholera LFA kit manufacturing.